---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007826"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:45:25.180207+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Q1 revenue $29M (+55% YoY), net loss ($9.0M), raises FY guidance to $128-133M

## Summary
- Revenue of $29.0M, up 55% from $18.7M in Q1 2021; driven by increased Lapiplasty kit sales and higher ASPs.
- Net loss attributable to common stockholders was ($9.0M), or ($0.16) per share, vs. ($2.6M) or ($0.07) in Q1 2021.
- Gross margin 81.0% (down from 82.2%); operating expenses rose to $31.6M from $16.8M on higher S&M and G&A investments.
- New five-year $150M loan arrangement ($120M term loan + $30M revolver); $54M drawn to repay existing $30M debt.
- FY 2022 revenue guidance raised to $128M-$133M (prior $125M-$130M); representing ~36%-41% YoY growth.

## SEC filing metadata
- accession: 0000950170-22-007826
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017022007826/0000950170-22-007826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017022007826/tmci-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007826
- JSON: https://secwatch.observer/filing/0000950170-22-007826.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.